Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Nuevolution A/S and Novo Nordisk A/S sign drug discovery collaboration


Copenhagen, Denmark - April 12th, 2005 -- Nuevolution A/S today announced the signing of a drug discovery collaboration in which Nuevolution will use its proprietary Chemetics® drug discovery technology to find new drug leads on targets provided by Novo Nordisk.

Knud Aunstrup, CEO of Nuevolution A/S commented “This agreement is an important milestone for Nuevolution. It will validate the use of our Chemetics® technology in drug discovery on targets of real interest. I am delighted that Novo Nordisk, one of Europe’s leading pharmaceutical companies with a long history of ground-breaking new developments in its area of expertise, has become Nuevolution’s first collaboration partner”.


About Nuevolution A/S

Nuevolution is poised to revolutionize the field of drug discovery by utilizing its proprietary Chemetics® technology to generate large numbers of potent, structurally diverse, small molecule drug leads to virtually any target in a matter of weeks.

Chemetics® represents the ultimate “convergent” drug discovery technology – it is a unique, patent protected hybrid of proven wet chemistry and molecular biology approaches that enables the synthesis of hundreds of millions of chemically diverse drug-like compounds and the accurate selection of target-specific hits in a matter of weeks.

Chemetics® allows Nuevolution to rapidly generate unprecedented numbers of potent and (target sub-type) selective drug leads, thus addressing a major current bottleneck in drug discovery and development.

Nuevolution seeks to leverage its broadly applicable Chemetics® drug discovery engine through drug discovery partnerships with leading pharmaceutical and biotechnology companies.

Nuevolution A/S employs some 30 world class scientists and business professionals, including 14 Ph.D. qualified individuals. The company was founded in May 2001 and is headquartered in Copenhagen, Denmark.

To date, Nuevolution has raised $ 27 million in venture capital financing based on the ongoing development of its proprietary Chemetics® technology. Investors in Nuevolution include Novo A/S, Nordic Biotech K/S, Scandinavian Life Science Venture, SEB Företagsinvest and Vaekstfonden.

For more information about Nuevolution A/S, please visit the company’s website www.nuevolution.com.
xx


Publisher Contact Information:

Nuevolution A/S
+45 39 13 09 44
ka@nuevolution.com

Company profile of Nuevolution A/S
Past press releases of Nuevolution A/S.

Data


25,444
Tech investments
From our Online Data Service
16,467
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Mar 15€0.5MInternet services
Mar 14€9.0MDatabase
Mar 14€18.0MInternet content
Mar 14N/AInternet services
Mar 14€4.0MMedical devices
Mar 8€9.0ME-Commerce
Mar 8€11.0MArtificial Intelligence

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises Ł1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.